ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
DOSAGE AND ADMINISTRATION
Important Safety Information
Verify pregnancy status of females of reproductive potential within 7 days prior to initiating ERIVEDGE [see Use In Specific Populations].
Recommended Dosage
The recommended dosage of ERIVEDGE is 150 mg taken orally once daily, with or without food, until disease progression or unacceptable toxicity.
Swallow the capsules whole. Do not open or crush capsules.
If a dose of ERIVEDGE is missed, resume dosing with the next scheduled dose.
Dosage Modifications For Adverse Reactions
Withhold ERIVEDGE for up to 8 weeks for intolerable adverse reactions until improvement or resolution. Treatment durations shorter than 8 weeks prior to interruptions have not been studied.
HOW SUPPLIED
Dosage Forms And Strengths
Capsules
150 mg with “150 mg” printed on pink opaque body and “VISMO” printed on grey opaque cap in black ink.
Storage And Handling
ERIVEDGE capsules have a pink opaque body and a grey opaque cap with "150 mg" printed on the capsule body and "VISMO" printed on the capsule cap in black ink.
ERIVEDGE capsules are available in bottles of 28 capsules (NDC 50242-140-01).
Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
No comments:
Post a Comment